Alnylam Pharmaceuticals Trading Volume Drops 40.88% to $520 Million, Ranks 172nd in Daily Volume

On March 24, 2025, Alnylam Pharmaceuticals (ALNY) saw a trading volume of $520 million, marking a 40.88% decrease from the previous day. The stock ranked 172nd in terms of trading volume for the day. ALNY's stock price increased by 2.60%, marking the fourth consecutive day of gains, with a total increase of 18.99% over the past four days.

JP Morgan upgraded its outlook for Alnylam Pharmaceuticals from Neutral to Overweight on March 24, 2025. This upgrade reflects a positive shift in the firm's assessment of the company's prospects. Capital World Investors holds 16,601K shares, representing 12.82% ownership, with a slight increase of 0.55% from its previous filing. However, the firm decreased its portfolio allocation in ALNY by 15.75% over the last quarter. AGTHX - GROWTH FUND OF AMERICA holds 10,568K shares, representing 8.16% ownership, with a decrease of 0.39% from its previous filing and a reduction in portfolio allocation by 10.78% over the last quarter. Capital Research Global Investors holds 6,969K shares, representing 5.38% ownership, with an increase of 24.75% from its previous filing and an increase in portfolio allocation by 12.47% over the last quarter. Regeneron Pharmaceuticals holds 4,444K shares, representing 3.43% ownership. T. Rowe Price Investment Management holds 4,384K shares, representing 3.39% ownership, with an increase of 28.40% from its previous filing and an increase in portfolio allocation by 22.24% over the last quarter.